Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Trial Profile

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Spartalizumab (Primary) ; Regorafenib
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 28 Jun 2019 Status changed from recruiting to completed.
  • 15 Apr 2019 Planned primary completion date changed from 3 Mar 2019 to 5 Jun 2019.
  • 13 Feb 2019 Status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top